文献速递系统性红斑狼疮

艾地苯醌减轻小鼠狼疮并改善线粒体代谢与炎症

Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone.
PubMed 文献 · Arthritis Rheumatol · 2020-01-27

研究在MRL/lpr和NZM2328狼疮小鼠模型中口服艾地苯醌(辅酶Q10合成醌类似物),发现其降低死亡率、减轻肾小球炎症和纤维化、改善肾功能,并抑制中性粒细胞胞外诱捕网形成、改善线粒体代谢和血管内皮功能,提示靶向线粒体药物可能对SLE有治疗作用。

要点

  • 艾地苯醌降低MRL/lpr狼疮小鼠死亡率并减轻肾小球炎症和纤维化。
  • 艾地苯醌抑制狼疮小鼠和SLE患者中性粒细胞胞外诱捕网形成。
  • 艾地苯醌改善线粒体代谢和血管内皮功能,减轻心脏脂质过氧化。

核心结论

  • 艾地苯醌改善小鼠狼疮疾病活动度和器官损伤严重程度,支持调节线粒体生物过程的药物可能在人类SLE中具有治疗作用。

研究设计与样本

  • MRL/lpr小鼠口服艾地苯醌(含药饮食1 gm/kg或1.5 gm/kg)8周,每组n=10,并与未治疗小鼠比较,结果在NZM2328狼疮小鼠模型中验证。

主要发现

  • MRL/lpr小鼠中艾地苯醌治疗组死亡率显著降低(P < 0.01),肾小球炎症和纤维化均减轻(各P < 0.05),肾功能改善伴肾脏IL-17A和成熟IL-18表达下降。
  • 艾地苯醌治疗组脾脏促炎细胞因子和炎症小体相关基因显著降低(至少P < 0.05,部分更高),未观察到明显药物毒性。
  • 艾地苯醌抑制狼疮倾向小鼠和人类SLE患者中性粒细胞胞外诱捕网形成(P < 0.05),并改善线粒体代谢(基础呼吸和ATP产生增加30%),心脏脂质过氧化减半,内皮依赖性血管舒张显著改善(P < 0.001)。
  • NZM2328小鼠中艾地苯醌改善肾脏和全身炎症,降低肾脏病理评分(P < 0.05)、IgG/C3沉积(P < 0.05)及干扰素、促炎和炎症小体相关基因表达(至少P < 0.05,部分更高)。

临床怎么用

  • 目前证据仅来自小鼠模型,尚不能直接推荐艾地苯醌用于人类SLE治疗,但支持进一步开展临床转化研究。

局限性

  • 研究限于小鼠狼疮模型,样本量每组n=10,尚未在人类SLE中验证疗效和安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A role for mitochondrial dysfunction has been proposed in the immune dysregulation and organ damage characteristic of systemic lupus erythematosus (SLE). Idebenone is a coenzyme Q10 synthetic quinone analog and an antioxidant that has been used in humans to treat diverse diseases in which mitochondrial function is impaired. This study was undertaken to assess whether idebenone ameliorates lupus in murine models. METHODS: Idebenone was administered orally to MRL/lpr mice at 2 different doses (1 gm/kg or 1.5 gm/kg idebenone-containing diet) for 8 weeks. At peak disease activity, clinical, immunologic, and metabolic parameters were analyzed and compared to those in untreated mice (n = 10 per treatment group). Results were confirmed in the lupus-prone NZM2328 mouse model. RESULTS: In MRL/lpr mice, idebenone-treated mice showed a significant reduction in mortality incidence (P < 0.01 versus untreated mice), and the treatment attenuated several disease features, including glomerular inflammation and fibrosis (each P < 0.05 versus untreated mice), and improved renal function in association with decreased renal expression of interleukin-17A (IL-17A) and mature IL-18. Levels of splenic proinflammatory cytokines and inflammasome-related genes were significantly decreased (at least P < 0.05 and some with higher significance) in mice treated with idebenone, while no obvious drug toxicity was observed. Idebenone inhibited neutrophil extracellular trap formation in neutrophils from lupus-prone mice (P < 0.05) and human patients with SLE. Idebenone also improved mitochondrial metabolism (30% increase in basal respiration and ATP production), reduced the extent of heart lipid peroxidation (by one-half that of untreated mice), and significantly improved endothelium-dependent vasorelaxation (P < 0.001). NZM2328 mice exposed to idebenone also displayed improvements in renal and systemic inflammation, reducing the kidney pathology score (P < 0.05), IgG/C3 deposition (P < 0.05), and the gene expression of interferon, proinflammatory, and inflammasome-related genes (at least P < 0.05 and some with higher significance). CONCLUSION: Idebenone ameliorates murine lupus disease activity and the severity of organ damage, supporting the hypothesis that agents that modulate mitochondrial biologic processes may have a therapeutic role in human SLE.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Blanco LP, Pedersen HL, Wang X, et al. Improved Mitochondrial Metabolism and Reduced Inflammation Following Attenuation of Murine Lupus With Coenzyme Q10 Analog Idebenone. Arthritis Rheumatol. 2020. PMID: 31566908. doi:10.1002/art.41128

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。